A pilot study intervention successfully provides mammograms for patients who face screening challenges.
Offering mammograms to inpatients could be a good way to screen women who might otherwise face challenges in getting imaged.
For many women, mammograms fall by the wayside either because they do not have transportation to the clinic or they cannot get time off work. To address this problem, investigators from Massachusetts General Hospital (MGH) tested an inpatient-mammogram intervention to see if it could be an easier way to tackle preventive care needs.
“We designed the study to reach the patients who face significant barriers to completing their mammograms in the outpatient setting,” said first author Andrew S. Hwang, M.D., MPH, and MGH internist.
Hwang’s team published their results in the January issue of Annals of Family Medicine.
Breast cancer screening rates are particularly low among Medicaid and dual-eligible patients, according to existing national and local data. If this intervention is successful, he said, it could help reduce disparities by simultaneously addressing patients’ acute and preventive care needs.
To test their intervention, Hwang’s team pinpointed women who were Medicaid and dual-eligible, had been admitted to MGH’s general medicine service between March 2019 and March 2020, and who were overdue for a mammogram. These inpatients also had a primary care provider associated with MGH with whom they could follow up for any abnormal results.
For more coverage based on industry expert insights and research, subscribe to the Diagnostic Imaging e-Newsletter here.
Overall, the team identified 21 women who met these criteria, and 17 went through with the inpatient mammogram – four were discharged before the screenings could be scheduled. For 35 percent of the screened group, this was their first mammogram – the remaining patients were overdue for a scan by an average of four years. All but one mammogram was negative, and providers recommended that patient pursue additional imaging to rule out cancer.
It is important to note, Hwang said, that scheduling a mammogram during the inpatient stay did not extend the patient’s hospitalization. Consequently, he and his team would like to extend the intervention to patients who are admitted into other areas of the hospital, as well as expand it to include other preventive services for low-income men and women, such as fecal immunochemical tests for colorectal cancer screening. Such innovative measures will be vital to addressing patients’ psychosocial needs and breaking down the barriers to care that many of them experience.
“[As] our healthcare system transitions from fee-for-service to value-based payment models, improving health outcomes among underserved patient populations will become increasingly important,” he said. “Completing preventive screening tests, such as mammograms, during hospitalizations can be one way to help patients who might otherwise miss preventive care.”
Study: Mammography AI Leads to 29 Percent Increase in Breast Cancer Detection
February 5th 2025Use of the mammography AI software had a nearly equivalent false positive rate as unassisted radiologist interpretation and resulted in a 44 percent reduction in screen reading workload, according to findings from a randomized controlled trial involving over 105,000 women.
Can AI Bolster Breast Cancer Detection in DBT Screening?
January 16th 2025In sequential breast cancer screening with digital breast tomosynthesis (DBT), true positive examinations had more than double the AI case score of true negative examinations and the highest positive AI score changes from previous exams, according to new research.
Mammography Study Suggests DBT-Based AI May Help Reduce Disparities with Breast Cancer Screening
December 13th 2024New research suggests that AI-powered assessment of digital breast tomosynthesis (DBT) for short-term breast cancer risk may help address racial disparities with detection and shortcomings of traditional mammography in women with dense breasts.
Mammography News: FDA Grants Expanded 510(k) Clearance for AI-Powered SmartMammo Dx DBT Software
November 29th 2024Originally cleared by the FDA in 2021, the SmartMammo Dx software for digital breast tomosynthesis (DBT) can now be utilized with the Senographe Pristina mammography systems from GE HealthCare.